Skip to main content
eligibility_summary
Eligible adults (≥18) planning inpatient CAR‑T for primary malignancy and fluent in English. Excludes those with speech/hearing issues preventing SALSA assessment, preexisting cognitive impairment, or inability/unwillingness to provide informed consent.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06414278 (status: Suspended) is an observational study evaluating a non-interventional digital tool, SALSA (Stress, Affect, Language and Speech Analysis), for early detection of cognitive side effects in adults receiving commercial CAR-T therapy. Intervention: SALSA automated cognitive testing alongside standard ICE assessments, no drugs are given. Mechanisms: SALSA functions as a diagnostic/monitoring analytics tool (automated speech/language/affect analysis). The underlying immunotherapy is CAR-T, an adoptive cellular therapy where engineered T lymphocytes express chimeric antigen receptors to recognize tumor antigens and drive cytotoxic activation. Cells/pathways targeted: CAR-T effector T cells, clinical focus is detection of immune effector cell–associated neurotoxicity syndrome (ICANS)/neuroinflammatory toxicity, not its modulation.